SEQUENT SCIENTIFIC
|
SEQUENT SCIENTIFIC Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 0.87 | -1.44 | -4.86 | 1.65 | 3.84 |
| CEPS(Rs) | 3.94 | 1.28 | -2.66 | 3.88 | 6.24 |
| DPS(Rs) | - | - | - | - | 0.50 |
| Book NAV/Share(Rs) | 24.28 | 23.22 | 25.76 | 25.97 | 28.98 |
| Tax Rate(%) | 27.19 | 45.81 | 11.39 | 15.43 | 23.55 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 9.94 | 4.35 | 0.82 | 7.59 | 15.13 |
| EBIT Margin(%) | 6.57 | -0.46 | -7.02 | 4.76 | 11.60 |
| Pre Tax Margin(%) | 2.77 | -3.87 | -9.47 | 3.67 | 9.84 |
| PAT Margin (%) | 2.02 | -2.10 | -8.39 | 3.10 | 7.53 |
| Cash Profit Margin (%) | 6.17 | 2.26 | -4.56 | 6.68 | 11.17 |
| Performance Ratios | |||||
| ROA(%) | 2.08 | -1.96 | -8.21 | 3.06 | 7.19 |
| ROE(%) | 5.44 | -4.85 | -18.95 | 6.56 | 15.00 |
| ROCE(%) | 9.30 | -0.60 | -9.71 | 7.01 | 16.24 |
| Asset Turnover(x) | 1.03 | 0.94 | 0.98 | 0.98 | 0.96 |
| Sales/Fixed Asset(x) | 1.63 | 1.49 | 1.65 | 1.83 | 1.83 |
| Working Capital/Sales(x) | 4.35 | 7.67 | 6.58 | 5.32 | 5.47 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.61 | 0.67 | 0.61 | 0.55 | 0.55 |
| Receivable days | 79.76 | 87.51 | 84.11 | 85.48 | 87.43 |
| Inventory Days | 83.50 | 89.54 | 87.10 | 77.50 | 63.61 |
| Payable days | 114.18 | 119.04 | 109.97 | 111.61 | 117.51 |
| Valuation Parameters | |||||
| PER(x) | 149.64 | - | - | 81.14 | 62.69 |
| PCE(x) | 33.17 | 90.08 | -27.32 | 34.51 | 38.59 |
| Price/Book(x) | 5.39 | 4.96 | 2.82 | 5.15 | 8.31 |
| Yield(%) | - | - | - | - | 0.21 |
| EV/Net Sales(x) | 2.35 | 2.38 | 1.52 | 2.53 | 4.52 |
| EV/Core EBITDA(x) | 20.69 | 45.01 | 118.11 | 29.76 | 27.91 |
| EV/EBIT(x) | 34.75 | -496.55 | -21.21 | 52.09 | 38.21 |
| EV/CE(x) | 3.17 | 2.94 | 1.98 | 2.41 | 4.26 |
| M Cap / Sales | 2.11 | 2.10 | 1.27 | 2.35 | 4.39 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 13.26 | -3.60 | 0.57 | 3.76 | 15.47 |
| Core EBITDA Growth(%) | 143.86 | 294.50 | -84.74 | -45.45 | 22.18 |
| EBIT Growth(%) | 1,701.48 | 93.58 | -248.67 | -57.33 | 24.06 |
| PAT Growth(%) | 208.94 | 75.72 | -372.49 | -57.14 | 27.31 |
| EPS Growth(%) | 160.78 | 70.40 | -394.57 | -57.09 | 36.53 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.73 | 0.78 | 0.62 | 0.49 | 0.31 |
| Current Ratio(x) | 1.68 | 1.28 | 1.40 | 1.50 | 1.49 |
| Quick Ratio(x) | 0.97 | 0.75 | 0.78 | 0.86 | 0.98 |
| Interest Cover(x) | 1.73 | -0.14 | -2.88 | 4.36 | 6.60 |
| Total Debt/Mcap(x) | 0.14 | 0.16 | 0.22 | 0.09 | 0.04 |
Compare Financial Ratios of peers of SEQUENT SCIENTIFIC
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SEQUENT SCIENTIFIC | ₹4,684.4 Cr | 0.9% | 2.4% | 33% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹403,712.0 Cr | -1.3% | 1% | 7.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹176,623.0 Cr | -3.2% | -0.3% | 48% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹120,285.0 Cr | 1.2% | 10.7% | 19.5% | Stock Analytics | |
| CIPLA | ₹119,010.0 Cr | -0.6% | -2.2% | -0.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,118.0 Cr | -1.5% | -5.9% | -5.1% | Stock Analytics | |
SEQUENT SCIENTIFIC Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SEQUENT SCIENTIFIC | 0.9% |
2.4% |
33% |
| SENSEX | 0.1% |
1% |
2.6% |
You may also like the below Video Courses
